Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353434 | 0.77 | SMN1; SMN2 (0.47) | RAB9ASMN1; SMN2NPC1ALDH1A1GABRA5 | |
| SCHEMBL4970134 | 0.76 | SMN1; SMN2 (0.59) | RAB9ASMN1; SMN2NPC1ALDH1A1GABRA5 | |
| SCHEMBL5913878 | 0.76 | HSD17B10 (0.48) | RAB9ASMN1; SMN2NPC1ALDH1A1GABRA5 | |
| Hydrochloric Acid SCHEMBL308085 | 0.74 | HSD17B10 (0.47) | RAB9ASMN1; SMN2NPC1ALDH1A1GABRA5 | |
| SCHEMBL5216503 | 0.73 | GABRA5 (0.40) | RAB9ASMN1; SMN2NPC1ALDH1A1GABRA5 | |
| SCHEMBL958545 | 0.72 | — | — | |
| SCHEMBL18284087 | 0.72 | MAP4K4 (0.37) | CNR1KCNH2ALDH1A1MAPTMAP4K4 | |
| Hydrochloric Acid SCHEMBL4796242 | 0.71 | SMN1; SMN2 (0.53) | RAB9ASMN1; SMN2NPC1ALDH1A1GABRA5 | |
| Hydrochloric Acid SCHEMBL4780449 | 0.71 | RAB9A (0.60) | RAB9ASMN1; SMN2NPC1ALDH1A1GABRA5 | |
| SCHEMBL5221488 | 0.70 | HSD17B10 (0.43) | RAB9ASMN1; SMN2NPC1ALDH1A1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716320-B2 | Antibacteriall heterocyclic ureas | REPLIDYNE, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20080207703-A1 | Antibacterial heterocyclic ureas | REPLIDYNE, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008011191-A1 | ANTIBACTERIAL HETEROCYCLIC UREAS | REPLIDYNE, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207703-A1 | Antibacterial heterocyclic ureas | UMPS, UROD, UGP2 | RAB9A 1509/4885SMN1; SMN2 4077/4885NPC1 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.